Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Motzer RJ, et al. Among authors: harmenberg u. N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989. N Engl J Med. 2013. PMID: 23964934 Free article. Clinical Trial.
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S. Escudier B, et al. Among authors: harmenberg u. Eur Urol. 2017 Sep;72(3):368-376. doi: 10.1016/j.eururo.2017.03.037. Epub 2017 Apr 12. Eur Urol. 2017. PMID: 28410865 Clinical Trial.
Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ. Escudier B, et al. Among authors: harmenberg u. J Clin Oncol. 2009 Sep 1;27(25):4068-75. doi: 10.1200/JCO.2008.20.5476. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652072 Clinical Trial.
Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
Ljungberg B, Sundqvist P, Lindblad P, Kjellman A, Thorstenson A, Hellström M, Kröger Dahlin BI, Thomasson M, Harmenberg U, Lundstam S. Ljungberg B, et al. Among authors: harmenberg u. Scand J Urol. 2020 Dec;54(6):487-492. doi: 10.1080/21681805.2020.1815833. Epub 2020 Sep 8. Scand J Urol. 2020. PMID: 32897123
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
Lindskog M, Wahlgren T, Sandin R, Kowalski J, Jakobsson M, Lundstam S, Ljungberg B, Harmenberg U. Lindskog M, et al. Among authors: harmenberg u. Urol Oncol. 2017 Sep;35(9):541.e15-541.e22. doi: 10.1016/j.urolonc.2017.05.013. Epub 2017 Jun 13. Urol Oncol. 2017. PMID: 28623071
53 results